Liver Cancer
Advertisement
Repeated use of TACE can impair liver function and stimulate tumor angiogenesis.
Dr. Richard Finn provides an overview of the key studies in liver cancer from ESMO 2024.
HIMALAYA found tremelimumab plus durvalumab to significantly improve overall survival over sorafenib alone.
FDA approval comes after the IMscin001 trial, an open-label, multi-center, international analysis of adult patients.
A study compared the outcomes of patients with HCC who underwent upfront surgical resection versus neoadjuvant immunotherapy.
Dr. Amit Mahipal discusses a recent study on atezolizumab plus bevacizumab as a first-line treatment for HCC.
Amezalpat is a PPAR⍺ antagonist that modulates immune suppressive cells and angiogenesis in the tumor microenvironment.
The FDA's decision to accept the sBLA is based on the encouraging results of the phase 3 CheckMate-9DW study.
Dr. Dan Kaufman discusses recent research on TGF-β and how it is linked to the development of HCC.
TACE may not be an optimal treatment strategy for patients with extensive tumor bulk or impaired liver function.
The study’s primary end point was overall survival in the inverse probability of treatment weighting.
While immunotherapy paired with VEGF inhibitors are considered first-line options, they only provide modest efficacy.
Dr. Luo describes the performance of the two-fusion gene + α-fetal protein logistic regression model.
Dr. Luo explains the potential benefits of machine learning for patients with hepatocellular carcinoma.
Median OS was 9.1 months for patients with CP-B7 and 4.7 months for those with CP-B8-C12.
The study investigated the Single Tremelimumab Regular Interval Durvalumab regimen.
While TACE is a common treatment for HCC, the procedure alone is associated with unsatisfactory survival benefits.
Dr. Luo and colleagues identified a need for increased screening measures for patients with HCC.
Patients then received 35 to 50 Gy of SBRT in 5 fractions, followed by an identical imaging process while waiting for a DDLT.
Integrated PET/MRI may be superior to PET/CT in diagnosing malignant tumor liver metastasis/lymphoma hepatic infiltration.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.